Impact of perioperative chemotherapy on survival outcomes among patients with metastatic colorectal cancer to the liver - Supplementary figures

<p>  </p> <p>Supplementary figure A. Median overall survival in the whole cohort according to the treatment modality after propensity score matching.</p> <p>  </p> <p>Supplementary figure B. Overall survival according to the treatment modality after excluding patients with 90-day mortality of most definitive primary site surgery after propensity score matching.</p> <p>  </p> <p>Supplementary figure C. Median overall survival comparison between single agent and multiagent chemotherapy after propensity score matching.</p> <p>  </p> <p>Supplementary figure D. Median overall survival comparison between adjuvant and neoadjuvant chemotherapy after propensity score matching.</p> <p>  </p> <p>Supplementary figure E. Median overall survival according to the treatment modality in (A) MSI-H and (B) MSI-L.</p> <p>  </p> <p>Supplementary figure F. Median overall survival comparison between single agent and multiagent chemotherapy in (A) MSI-H and (B) MSI-L.</p> <p>  </p> <p>Supplementary figure G. Median overall survival comparison between adjuvant and neoadjuvant chemotherapy in (A) MSI-H and (B) MSI-L.</p> <p><br></p>